Skip to content

Efficacy and safety ofa New anti-redness moisturizing tolerance-extreme cream containing angelica sinensis and porphyridium in the treatment of sensitive skin: A randomized, double-blind, placebo-controlled clinical trial

Efficacy and safety of a New anti-redness moisturizing tolerance-extreme cream containing angelica sinensis and porphyridium in the treatment of sensitive skin: A randomized, double-blind, placebo-controlled clinical trial

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900023439
Enrollment
Unknown
Registered
2019-05-27
Start date
2019-06-02
Completion date
Unknown
Last updated
2019-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sensitive skin

Interventions

Control group:Avene relief concentrate for chronic redness cream
Experiment group:a New anti-redness moisturizing tolerance-extreme cream

Sponsors

The First Hospital Affiliated of Kunming Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1 Aged 18-55 years, female; 2 Clinical manifestations of sensitive skin; (1) subjective symptoms: usually by physical, chemical, mental and other stimulation of the skin after different degrees of burning, tingling, itching, and tight feeling and other symptoms, lasting a few minutes or even a few hours, often can not tolerate ordinary skin care products. (2) objective signs: the appearance of sensitive skin is mostly normal, a few people face skin can appear flaky or diffuse flush, erythema, telangiectasia, can be accompanied by dry, small scales. 3 lactic acid test score= 3; 4 subjects are willing to use no other skin care products and receive other facial treatments (such as drugs, chemical stripping, laser, etc.) during the entire study period; 5 observe the test requirements throughout the study period, complete the entire test, and be able to complete the follow-up as required; 6 the informed consent has been signed and the researcher is willing to complete the study.

Exclusion criteria

Exclusion criteria: 1 Patients with severe heart, kidney, liver, endocrine and other systemic diseases or with tumor and immunodeficiency diseases; 2 pregnant, pregnant or lactating women; 3 used other blush products or received other one month before the study Treatment methods (such as: drugs, radio frequency laser, etc.) 4 other skin diseases such as: hormone-dependent dermatitis, hemorrhoids, rose acne, etc.; 5 known to be allergic to the test substance 6 staff directly involved in the study; 7 currently participating in other clinical studies or participating within 3 months Patients who have undergone other clinical studies.

Design outcomes

Primary

MeasureTime frame
Lab (CM-2600d, Minolta, Japan);VISIA(VISIA-CR, Canfield, USA).;Skin physiology function test(MX 18;Courage &Khazaka, Germany);Subjects Assessment;Dermoscopy;Confocal scanning laser microscopy (CSLM);

Countries

China

Contacts

Public ContactLi He

The First Hospital Affiliated of Kunming Medical University

drheli2662@126.com+86 13608711764

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026